U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19N5O2.2C4H4O4
Molecular Weight 557.5094
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of PIXANTRONE DIMALEATE

SMILES

OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O

InChI

InChIKey=SVAGFBGXEWPNJC-SPIKMXEPSA-N
InChI=1S/C17H19N5O2.2C4H4O4/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24;2*5-3(6)1-2-4(7)8/h1-3,6,9,21-22H,4-5,7-8,18-19H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C17H19N5O2
Molecular Weight 325.3651
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf | https://www.medicines.org.uk/emc/PIL.30473.latest.pdf

Pixantrone is a novel anthracenedione. It is a weak inhibitor of topoisomerase II. Pixantrone directly alkylates DNA forming stable DNA adducts and cross-strand breaks. Pixuvri is approved for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin lymphomas. It is used for patients whose cancer does not respond or has returned after they have received other chemotherapy treatments. The most frequent AE were seen in the blood (mainly neutropaenia), gastrointestinal (nausea, abdominal pain, constipation) and respiratory systems (cough, dyspnea). No drug-drug interaction studies have been submitted and no drug interactions have been reported in human subjects

CNS Activity

Curator's Comment: Known to be CNS penetrant in rodents. Human data not available.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Pixuvri

Approved Use

Pixuvri is used for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin lymphomas.

Launch Date

2012
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
52.4 nM
5 mg/m² single, intravenous
dose: 5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
213.2 nM
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
483.2 nM
16.5 mg/m² single, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
762.4 nM
25 mg/m² single, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1189.6 nM
35 mg/m² single, intravenous
dose: 35 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1447.5 nM
56 mg/m² single, intravenous
dose: 56 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2241.9 nM
84 mg/m² single, intravenous
dose: 84 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
318.1 nM
16.5 mg/m² 1 times / week multiple, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
701.4 nM
25 mg/m² 1 times / week multiple, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1193 nM
37.5 mg/m² 1 times / week multiple, intravenous
dose: 37.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
4297.6 nM
75 mg/m² 1 times / week multiple, intravenous
dose: 75 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7120.8 nM
112.5 mg/m² 1 times / week multiple, intravenous
dose: 112.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
3852.1 nM
150 mg/m² 1 times / week multiple, intravenous
dose: 150 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
438.1 nM × h
5 mg/m² single, intravenous
dose: 5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
451.1 nM × h
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
781.9 nM × h
16.5 mg/m² single, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1321.2 nM × h
25 mg/m² single, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2530.5 nM × h
35 mg/m² single, intravenous
dose: 35 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2266.8 nM × h
56 mg/m² single, intravenous
dose: 56 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3679.9 nM × h
84 mg/m² single, intravenous
dose: 84 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
502.6 nM × h
16.5 mg/m² 1 times / week multiple, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1074.8 nM × h
25 mg/m² 1 times / week multiple, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1773.4 nM × h
37.5 mg/m² 1 times / week multiple, intravenous
dose: 37.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
5027.1 nM × h
75 mg/m² 1 times / week multiple, intravenous
dose: 75 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7882.3 nM × h
112.5 mg/m² 1 times / week multiple, intravenous
dose: 112.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
8058.5 nM × h
150 mg/m² 1 times / week multiple, intravenous
dose: 150 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
982 ng × h/mL
33 mg/m² 1 times / week multiple, intravenous
dose: 33 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1727 ng × h/mL
49 mg/m² 1 times / week multiple, intravenous
dose: 49 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3811 ng × h/mL
88 mg/m² 1 times / week multiple, intravenous
dose: 88 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
36.3 h
5 mg/m² single, intravenous
dose: 5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21.4 h
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20.8 h
16.5 mg/m² single, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.7 h
25 mg/m² single, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
31.9 h
35 mg/m² single, intravenous
dose: 35 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.3 h
56 mg/m² single, intravenous
dose: 56 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.5 h
84 mg/m² single, intravenous
dose: 84 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.23 h
16.5 mg/m² 1 times / week multiple, intravenous
dose: 16.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
16.46 h
25 mg/m² 1 times / week multiple, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
13.77 h
37.5 mg/m² 1 times / week multiple, intravenous
dose: 37.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
8.89 h
75 mg/m² 1 times / week multiple, intravenous
dose: 75 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
9.5 h
112.5 mg/m² 1 times / week multiple, intravenous
dose: 112.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
11.91 h
150 mg/m² 1 times / week multiple, intravenous
dose: 150 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
23.3 h
33 mg/m² 1 times / week multiple, intravenous
dose: 33 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
23.3 h
49 mg/m² 1 times / week multiple, intravenous
dose: 49 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
23.3 h
88 mg/m² 1 times / week multiple, intravenous
dose: 88 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
33 mg/m² 1 times / week multiple, intravenous
dose: 33 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
50%
49 mg/m² 1 times / week multiple, intravenous
dose: 49 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
50%
88 mg/m² 1 times / week multiple, intravenous
dose: 88 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PIXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
240 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 240 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 240 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
DLT: Neutropenia...
Other AEs: Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 40%)
Other AEs:
Thrombocytopenia (grade 4, 20%)
Sources:
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
DLT: Neutropenia...
Other AEs: Neutropenia, Thrombopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 50%)
Other AEs:
Neutropenia (grade 3, 50%)
Thrombopenia (grade 4, 16.7%)
Anemia (grade 3, 16.7%)
Diarrhea (grade 4, 16.7%)
Vomiting (grade 4, 16.7%)
Sources:
180 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 180 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 3, 33.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 20%
240 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 240 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 240 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neutropenia grade 4, 40%
DLT
240 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 240 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 240 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Anemia grade 3, 16.7%
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neutropenia grade 3, 50%
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Diarrhea grade 4, 16.7%
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Thrombopenia grade 4, 16.7%
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Vomiting grade 4, 16.7%
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neutropenia grade 4, 50%
DLT
84 mg/m2 1 times / week multiple, intravenous
Highest studied dose|RP2D
Dose: 84 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 84 mg/m2, 1 times / week
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neutropenia grade 3, 33.3%
180 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 180 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [IC50 18.9991 uM]
likely
likely
moderate
no
weak
weak
weak
weak
yes [IC50 1.8999 uM]
yes [IC50 2.6837 uM]
yes
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
1995 Jul
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
2001 May
Pixantrone (Novuspharma).
2003 May
A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
2004 Apr
New immunosuppressants with potential implication in multiple sclerosis.
2004 Aug 15
Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
2004 Aug 15
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
2004 Jun
The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
2005 Aug
Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis.
2005 Nov
Diagnosis and management of lymphoma.
2006 Jul
EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
2006 Sep
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.
2007
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
2007 Feb
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
2007 Jun
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.
2007 Jun
Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
2007 Oct
Considerations with newer regimens for indolent non-Hodgkin lymphoma.
2008 Aug
Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats.
2008 Feb 15
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones.
2008 Feb 28
Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.
2008 Jul
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.
2009 Apr
Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
2009 May
Pixantrone maleate for non-Hodgkin's lymphoma.
2009 Nov
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
2010 Aug
DNA binding by pixantrone.
2010 Dec 7
Lymphoma researchers in search of molecular targets.
2010 Jul 21
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
2010 Nov
New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
2010 Oct 14
Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis.
2013 May 15
Patents

Patents

Sample Use Guides

The recommended dose is 50 mg/m^2 of pixantrone on day 1, 8 and 15 of each 28-day cycle for up to 6 cycles.
Route of Administration: Intravenous
In separate 72-hour growth-inhibitory assays using direct cell counting, the etoposide-resistant K/VP.5 cells were 21.6-fold cross-resistant to pixantrone, yielding IC50 values of 0.04 and 0.85 uM for K562 and K/VP.5 cells, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:57:20 GMT 2025
Edited
by admin
on Mon Mar 31 17:57:20 GMT 2025
Record UNII
P0R64C4CR9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIXANTRONE DIMALEATE SALT
MI  
Preferred Name English
PIXANTRONE DIMALEATE
DASH   USAN  
USAN  
Official Name English
BBR 2778 DIMALEATE
Code English
Pixantrone maleate [WHO-DD]
Common Name English
PIXANTRONE DIMALEATE SALT [MI]
Common Name English
PIXUVRI
Brand Name English
PIXANTRONE DIMALEATE [USAN]
Common Name English
6,9-Bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione (2Z)-but-2-enedioate (1:2)
Systematic Name English
BENZ(G)ISOQUINOLINE-5,10-DIONE, 6,9-BIS((2-AMINOETHYL)AMINO)-, (2Z)-2-BUTENEDIOATE (1:2)
Systematic Name English
BBR-2778 DIMALEATE
Code English
PIXANTRONE MALEATE
WHO-DD  
Common Name English
NSC-752341
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/09/722
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
EMA ASSESSMENT REPORTS PIXUVRI (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
NCI_THESAURUS C582
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
Code System Code Type Description
FDA UNII
P0R64C4CR9
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
PUBCHEM
9937618
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
NCI_THESAURUS
C82398
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
CAS
144675-97-8
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
MERCK INDEX
m8898
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY Merck Index
SMS_ID
100000124199
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
EVMPD
SUB31562
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
DRUG BANK
DBSALT000141
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
NSC
752341
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
USAN
WW-63
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
ChEMBL
CHEMBL167731
Created by admin on Mon Mar 31 17:57:20 GMT 2025 , Edited by admin on Mon Mar 31 17:57:20 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY